Fortrea Holdings Inc. (FTRE) stock surged 5.11% in pre-market trading on Tuesday, despite the company reporting disappointing fourth-quarter 2024 results and issuing weaker-than-expected guidance for 2025.
In its Q4 2024 earnings report, Fortrea disclosed a 1.8% year-over-year decline in revenue to $697 million, primarily due to lower late-stage clinical service fee revenue. The company's adjusted EBITDA margin for the full year 2024 also decreased to 7.5%, down from 8.6% in 2023, impacted by the lower revenues and higher SG&A expenses.
Fortrea's net loss for the full year 2024 ballooned to $271.5 million, a significant increase from the $31.7 million net loss reported in 2023. The company attributed the larger net loss to the impact of pre-spin projects with lower revenue and profitability, as well as higher SG&A costs related to professional fees and exiting transition services with its former parent company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.